51
|
Sciutto E, Rosas G, Cruz-Revilla C, Toledo A, Cervantes J, Hernández M, Hernándezt B, Goldbaum FA, de Aluja AS, Fragoso G, Larralde C. Renewed hope for a vaccine against the intestinal adult Taenia solium. J Parasitol 2010; 93:824-31. [PMID: 17918361 DOI: 10.1645/ge-1018r1.1] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
Review of experimental and observational evidence about various cestode infections of mammalian hosts revives hope for the development of an effective vaccine against adult intestinal tapeworms, the central protagonists in their transmission dynamics. As for Taenia solium, there are abundant immunological data regarding cysticercosis in humans and pigs, but information about human taeniasis is scarce. A single publication reporting protection against T. solium taeniasis by experimental primo infection and by vaccination of an experimental foster host, the immunocompetent female hamster, kindles the hope of a vaccine against the tapeworm to be used in humans, its only natural definitive host.
Collapse
Affiliation(s)
- Edda Sciutto
- Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, A.P. 70228, DF México.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
52
|
Rassy D, Bobes RJ, Rosas G, Anaya VH, Brehm K, Hernández B, Cervantes J, Pedraza S, Morales J, Villalobos N, de Aluja AS, Laclette JP, Nunes CM, Biondi GF, Fragoso G, Hernández M, Sciutto E. Characterization of S3Pvac anti-cysticercosis vaccine components: implications for the development of an anti-cestodiasis vaccine. PLoS One 2010; 5:e11287. [PMID: 20585656 PMCID: PMC2890579 DOI: 10.1371/journal.pone.0011287] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2009] [Accepted: 06/02/2010] [Indexed: 11/19/2022] Open
Abstract
Background Cysticercosis and hydatidosis seriously affect human health and are responsible for considerable economic loss in animal husbandry in non-developed and developed countries. S3Pvac and EG95 are the only field trial-tested vaccine candidates against cysticercosis and hydatidosis, respectively. S3Pvac is composed of three peptides (KETc1, GK1 and KETc12), originally identified in a Taenia crassiceps cDNA library. S3Pvac synthetically and recombinantly expressed is effective against experimentally and naturally acquired cysticercosis. Methodology/Principal Findings In this study, the homologous sequences of two of the S3Pvac peptides, GK1 and KETc1, were identified and further characterized in Taenia crassiceps WFU, Taenia solium, Taenia saginata, Echinococcus granulosus and Echinococcus multilocularis. Comparisons of the nucleotide and amino acid sequences coding for KETc1 and GK1 revealed significant homologies in these species. The predicted secondary structure of GK1 is almost identical between the species, while some differences were observed in the C terminal region of KETc1 according to 3D modeling. A KETc1 variant with a deletion of three C-terminal amino acids protected to the same extent against experimental murine cysticercosis as the entire peptide. On the contrary, immunization with the truncated GK1 failed to induce protection. Immunolocalization studies revealed the non stage-specificity of the two S3Pvac epitopes and their persistence in the larval tegument of all species and in Taenia adult tapeworms. Conclusions/Significance These results indicate that GK1 and KETc1 may be considered candidates to be included in the formulation of a multivalent and multistage vaccine against these cestodiases because of their enhancing effects on other available vaccine candidates.
Collapse
Affiliation(s)
- Dunia Rassy
- Departamento de Inmunología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Distrito Federal, México
| | - Raúl J. Bobes
- Departamento de Inmunología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Distrito Federal, México
| | - Gabriela Rosas
- Facultad de Medicina, Universidad Autónoma del Estado de Morelos. Cuernavaca, Morelos, México
| | - Victor H. Anaya
- Institute for Theoretical Biology, Humboldt Universität zu Berlin, Berlin, Germany
| | - Klaus Brehm
- Institut für Hygiene und Mikrobiologie, Julius-Maximillians-Universität Würzburg, Würzburg, Germany
| | - Beatriz Hernández
- Facultad de Medicina, Universidad Nacional Autónoma de México, Distrito Federal, México
| | - Jacquelynne Cervantes
- Departamento de Inmunología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Distrito Federal, México
| | - Saúl Pedraza
- Departamento de Inmunología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Distrito Federal, México
| | - Julio Morales
- Departamento de Inmunología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Distrito Federal, México
| | - Nelly Villalobos
- Facultad de Medicina Veterinaria y Zootecnia, Universidad Nacional Autónoma de México, Distrito Federal, México
| | - Aline S. de Aluja
- Facultad de Medicina Veterinaria y Zootecnia, Universidad Nacional Autónoma de México, Distrito Federal, México
| | - Juan P. Laclette
- Departamento de Inmunología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Distrito Federal, México
| | - Caris M. Nunes
- Departamento de Apoio, Produção e Saúde Animal, Campus de Araçatuba, Universidad Estadual Paulista “Júlio de Mesquita Filho, Araçatuba, São Paolo, Brazil
| | - Germano F. Biondi
- Departamento de Higiene Veterinária e Saúde Pública, Faculdade de Medicina Veterinária e Zootecnia de Botucatu, Campus Botucatu, Universidad Estadual Paulista “Júlio de Mesquita Filho, Botucatu, São Paolo, Brazil
| | - Gladis Fragoso
- Departamento de Inmunología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Distrito Federal, México
| | - Marisela Hernández
- Departamento de Inmunología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Distrito Federal, México
| | - Edda Sciutto
- Departamento de Inmunología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Distrito Federal, México
- * E-mail:
| |
Collapse
|
53
|
Evaluation of humoral and cellular immune responses against HSV-1 using genetic immunization by filamentous phage particles: a comparative approach to conventional DNA vaccine. J Virol Methods 2009; 163:440-4. [PMID: 19903497 DOI: 10.1016/j.jviromet.2009.11.008] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2009] [Revised: 10/31/2009] [Accepted: 11/03/2009] [Indexed: 01/09/2023]
Abstract
Phage display is based on expressing peptides as a fusion to one of the phage coat proteins. To date, many vaccine researches have been conducted to display immunogenic peptides or mimotopes of various pathogens and tumors on the surface of filamentous bacteriophages. In recent years as a new approach to application of phages, recombinant bacteriophage lambda particles were used as DNA delivery vehicles to mammalian cells. In this study, recombinant filamentous phage whole particles were used for vaccination of mice. BALB/c mice were inoculated with filamentous phage particles containing expression cassette of Herpes simplex virus 1 (HSV-1) glycoprotein D that has essential roles in the virus attachment and entry. Both humoral and cellular immune responses were measured in the immunized mice and compared to conventional DNA vaccination. A dose-response relationship was observed in both arms of immune responses induced by recombinant filamentous phage inoculation. The results were similar to those from DNA vaccination. Filamentous phages can be considered as suitable alternative candidate vaccines because of easier and more cost-effective production and purification over plasmid DNA or bacteriophage lambda particles.
Collapse
|
54
|
Pedroza-Roldan C, Charles-Niño C, Saavedra R, Govezensky T, Vaca L, Avaniss-Aghajani E, Gevorkian G, Manoutcharian K. Variable epitope library-based vaccines: shooting moving targets. Mol Immunol 2009; 47:270-82. [PMID: 19853920 DOI: 10.1016/j.molimm.2009.09.024] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2009] [Accepted: 09/09/2009] [Indexed: 11/19/2022]
Abstract
While the antigenic variability is the major obstacle for developing vaccines against antigenically variable pathogens (AVPs) and cancer, this issue is not addressed adequately in current vaccine efforts. We developed a novel variable epitope library (VEL)-based vaccine strategy using immunogens carrying a mixture of thousands of variants of a single epitope. In this proof-of-concept study, we used an immunodominant HIV-1-derived CD8+ cytotoxic T-lymphocyte (CTL) epitope as a model antigen to construct immunogens in the form of plasmid DNA and recombinant M13 bacteriophages. We generated combinatorial libraries expressing epitope variants with random amino acid substitutions at 2-5 amino acid positions within the epitope. Mice immunized with these immunogens developed epitope-specific CD8+ IFN-gamma+ T-cell responses that recognized more than 50% of heavily mutated variants of wild-type epitope, as demonstrated in T-cell proliferation assays and FACS analysis. Strikingly, these potent and broad epitope-specific immune responses were long lasting: after 12 months of priming, epitope variants were recognized by CD8+ cells and effector memory T cells were induced. In addition, we showed, for the first time, the inhibition of T-cell responses at the molecular level by immune interference: the mice primed with wild-type epitope and 8 or 12 months later immunized with VELs, were not able to recognize variant epitopes efficiently. These data may give a mechanistic explanation for the failure of recent HIV vaccine trials as well as highlight specific hurdles in current molecular vaccine efforts targeting other important antigenically variable pathogens and diseases. These findings suggest that the VEL-based strategy for immunogen construction can be used as a reliable technological platform for the generation of vaccines against AVPs and cancer, and contribute to better understanding complex host-pathogen interactions.
Collapse
Affiliation(s)
- Cesar Pedroza-Roldan
- Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, AP 70228, Cuidad Universitaria, México DF 04510, Mexico
| | | | | | | | | | | | | | | |
Collapse
|
55
|
McCullough KC, Summerfield A. Targeting the porcine immune system--particulate vaccines in the 21st century. DEVELOPMENTAL AND COMPARATIVE IMMUNOLOGY 2009; 33:394-409. [PMID: 18771683 PMCID: PMC7103233 DOI: 10.1016/j.dci.2008.07.015] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/19/2008] [Revised: 07/11/2008] [Accepted: 07/11/2008] [Indexed: 05/15/2023]
Abstract
During the last decade, the propagation of immunological knowledge describing the critical role of dendritic cells (DC) in the induction of efficacious immune responses has promoted research and development of vaccines systematically targeting DC. Based on the promise for the rational design of vaccine platforms, the current review will provide an update on particle-based vaccines of both viral and synthetic origin, giving examples of recombinant virus carriers such as adenoviruses and biodegradable particulate carriers. The viral carriers carry pathogen-associated molecular patterns (PAMP), used by the original virus for targeting DC, and are particularly efficient and versatile gene delivery vectors. Efforts in the field of synthetic vaccine carriers are focussing on decorating the particle surface with ligands for DC receptors such as heparan sulphate glycosaminoglycan structures, integrins, Siglecs, galectins, C-type lectins and toll-like receptors. The emphasis of this review will be placed on targeting the porcine immune system, but reference will be made to advances with murine and human vaccine delivery systems where information on DC targeting is available.
Collapse
Affiliation(s)
- Kenneth C McCullough
- Institute of Virology and Immunoprophylaxis, Sensemattstrasse 293, CH-3147 Mittelhäusern, Switzerland.
| | | |
Collapse
|
56
|
Petrenko V. Evolution of phage display: from bioactive peptides to bioselective nanomaterials. Expert Opin Drug Deliv 2008; 5:825-36. [PMID: 18712993 DOI: 10.1517/17425247.5.8.825] [Citation(s) in RCA: 76] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
BACKGROUND New phage-derived biorecognition nanomaterials have emerged recently as a result of the in-depth study of the genetics and structure of filamentous phage and the evolution of phage display technology. OBJECTIVE This review focuses on the progress made in the development of these new nanomaterials and discusses the prospects of using phage as a bioselectable molecular recognition interface in medical and technical devices. METHODS The author used data obtained both in his research group and sourced using Science Citation Index (Web of Science) search resources. RESULTS/CONCLUSION The merging of phage display technologies with nanotechnology over the past few years has proved promising and has already shown its vitality and productivity by contributing vigorously to different areas of medicine and technology, such as medical diagnostics and monitoring, molecular imaging, targeted drug and gene delivery, vaccine development, as well as bone and tissue repair.
Collapse
Affiliation(s)
- Va Petrenko
- Auburn University, Department of Pathobiology, AL 36849, USA.
| |
Collapse
|
57
|
Morales J, Martínez JJ, Manoutcharian K, Hernández M, Fleury A, Gevorkian G, Acero G, Blancas A, Toledo A, Cervantes J, Maza V, Quet F, Bonnabau H, de Aluja AS, Fragoso G, Larralde C, Sciutto E. Inexpensive anti-cysticercosis vaccine: S3Pvac expressed in heat inactivated M13 filamentous phage proves effective against naturally acquired Taenia solium porcine cysticercosis. Vaccine 2008; 26:2899-905. [PMID: 18440675 DOI: 10.1016/j.vaccine.2008.03.042] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2008] [Revised: 03/16/2008] [Accepted: 03/19/2008] [Indexed: 10/22/2022]
Abstract
In search of reducing vaccine production costs', a recombinant M13 phage version of the anti-cysticercosis tripeptide vaccine (S3Pvac) was developed. The efficacy of S3Pvac-Phage vs. placebo was evaluated in a randomized trial that included 1,047 rural pigs in 16 villages of Central Mexico. Three to five months after vaccination 530 pigs were examined by tongue inspection. At 5-27 months of age, 331 pigs (197 vaccinated/134 controls) were inspected at necropsy. Vaccination reduced 70% the frequency of tongue cysticercosis and, based on necropsy, 54% of muscle-cysticercosis and by 87% the number of cysticerci.
Collapse
Affiliation(s)
- Julio Morales
- Facultad de Medicina Veterinaria y Zootecnia, Universidad Nacional Autónoma de México, México, D.F. 04510, Mexico
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
58
|
Gu Y, Li J, Zhu X, Yang J, Li Q, Liu Z, Yu S, Li Y. Trichinella spiralis: Characterization of phage-displayed specific epitopes and their protective immunity in BALB/c mice. Exp Parasitol 2008; 118:66-74. [PMID: 17707815 DOI: 10.1016/j.exppara.2007.06.014] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2007] [Revised: 06/06/2007] [Accepted: 06/25/2007] [Indexed: 11/28/2022]
Abstract
Trichinellosis is a global zoonosis mainly caused by Trichinella spiralis. We have previously reported that a novel Ts87 gene from the cDNA library of adult T. spiralis was cloned and expressed in a prokaryotic expression system. Vaccination with recombinant Ts87 protein (rTs87) induced a muscle larvae burden reduction in BALB/c mice by 29% in response to T. spiralis infection. In the present study, we screened a random phage-displayed peptide library using monoclonal antibody 5A3 which recognized Ts87 protein. Four positive phage clones were selected to subcutaneously immunize BALB/c mice without adjuvant. Two phage clones could effectively stimulate specific antibodies against rTs87. Mice vaccinated with these two combined phage clones showed a 28.7% worm burden reduction as compared to the control group. Therefore, the identified phage clones displayed peptides representing specific epitopes of Ts87 protein and could be considered as potential vaccine candidates for T. spiralis.
Collapse
Affiliation(s)
- Yuan Gu
- Department of Parasitology, School of Basic Medical Sciences, Capital Medical University, Beijing 100069, PR China
| | | | | | | | | | | | | | | |
Collapse
|
59
|
Effective production and purification of the glycosylated TSOL18 antigen, which is protective against pig cysticercosis. Infect Immun 2007; 76:767-70. [PMID: 18070907 DOI: 10.1128/iai.00444-07] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Cysticercosis caused by Taenia solium metacestodes is a worldwide public health problem. Important progress in the development of effective and practical vaccines against this disease has been made. In this study, the promising T. solium oncospheral vaccine candidate named TSOL18 antigen was produced in a 5-liter fermentor. During the process of fermentation, the pH of the culture was always kept below 5.0, and in order to prevent foaming, an antifoam agent was added. In addition, the oxygen content of the culture was constantly kept at >50% in our experiment. A high level of the glycosylated protein (2.5 g/liter) was obtained, and the protein was easily purified by gel chromatography. Vaccination trials showed that the recombinant TSOL18 antigen induced 94 and 100% reductions in metacestode burdens in vaccinated pigs, obviously higher than the 89% reduction in pigs immunized with cysticercus crude extracts in trial 1. These are very promising results in the development of an efficient tool to control cysticercosis in Asia.
Collapse
|
60
|
Hernández M, Cabrera-Ponce JL, Fragoso G, López-Casillas F, Guevara-García A, Rosas G, León-Ramírez C, Juárez P, Sánchez-García G, Cervantes J, Acero G, Toledo A, Cruz C, Bojalil R, Herrera-Estrella L, Sciutto E. A new highly effective anticysticercosis vaccine expressed in transgenic papaya. Vaccine 2007; 25:4252-60. [PMID: 17399859 DOI: 10.1016/j.vaccine.2007.02.080] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2006] [Revised: 02/20/2007] [Accepted: 02/23/2007] [Indexed: 10/23/2022]
Abstract
The use of transgenic plants as new antigen-delivery systems for subunit vaccines has been increasingly explored. We herein report progress toward a papaya-based vaccine against cysticercosis. Synthetic peptides (KETc1, KETc12, KETc7) were successfully expressed in 19 different transgenic papaya clones and found to be immunogenic. Complete protection against cysticercosis was induced with the soluble extract of the clones that expressed the higher levels of transcripts in up to 90% of the immunized mice. This study represents a key step towards the development of a more effective, sustainable and affordable oral subunit vaccine against human and pig cysticercosis.
Collapse
MESH Headings
- Animals
- Carica/genetics
- Cysticercosis/immunology
- Cysticercosis/prevention & control
- Cysticercus/growth & development
- Cysticercus/immunology
- Female
- Life Cycle Stages
- Mice
- Mice, Inbred BALB C
- Models, Animal
- Peritoneal Cavity/parasitology
- Plants, Genetically Modified/genetics
- Plants, Genetically Modified/metabolism
- Vaccines, Subunit/genetics
- Vaccines, Subunit/immunology
- Vaccines, Subunit/isolation & purification
- Vaccines, Synthetic/genetics
- Vaccines, Synthetic/immunology
- Vaccines, Synthetic/isolation & purification
Collapse
Affiliation(s)
- Marisela Hernández
- Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, México, D.F. 04510, México
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
61
|
Guo A, Jin Z, Zheng Y, Hai G, Yuan G, Li H, Cai X. Induction of protection against porcine cysticercosis in growing pigs by DNA vaccination. Vaccine 2007; 25:170-5. [PMID: 16750874 DOI: 10.1016/j.vaccine.2006.03.073] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2005] [Revised: 03/07/2006] [Accepted: 03/14/2006] [Indexed: 11/23/2022]
Abstract
A DNA vaccine, pcDNA3-B, was developed by using the nucleotide sequence of Taenia solium B antigen and cloning into pcDNA3.1 plasmid. The growing pigs were vaccinated by one intramuscular infection of 200 or 1000 microg pcDNA3-B. The immunization with 1000 microg of pcDNA3-B showed 92.6% protection when the pigs were challenged by T. solium eggs and four of the five pigs vaccinated had no viable cysts. The results provide encouraging information on the use of pcDNA3-B vaccination for the prevention of cysticercosis.
Collapse
Affiliation(s)
- Aijiang Guo
- Key Laboratory of Veterinary Parasitology of Gansu Province, State Key Laboratory of Veterinary Etiological Biology, Lanzhou Veterinary Research Institute, CAAS, Lanzhou, Gansu 730046, China
| | | | | | | | | | | | | |
Collapse
|
62
|
De Berardinis P, Haigwood NL. New recombinant vaccines based on the use of prokaryotic antigen-display systems. Expert Rev Vaccines 2006; 3:673-9. [PMID: 15606352 DOI: 10.1586/14760584.3.6.673] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
A major challenge in vaccine design has been to identify antigen presentation systems that elicit strong T- and B-cell responses. In the authors' laboratory, two new delivery vehicles derived from nonpathogenic prokaryotic organisms were recently designed and investigated. Conserved antigenic determinants were inserted into the N-terminal region of the major pVIII coat protein of bacteriophage fd virions or on the surface of an icosahedral scaffold formed by the acyltransferase component (E2 protein) of the pyruvate dehydrogenase complex of Bacillus stearothermophilus. The data indicate that the antigenic determinant displayed by either fd virions or on the surface of the E2 lattice are accessible to the immune system, and are able to trigger a humoral response as well as a potent helper and cytolytic response in vitro and in vivo. These systems offer the potential for safe and inexpensive vaccines to elicit full-spectrum immune responses.
Collapse
|
63
|
Sciutto E, Rosas G, Hernández M, Morales J, Cruz-Revilla C, Toledo A, Manoutcharian K, Gevorkian G, Blancas A, Acero G, Hernández B, Cervantes J, Bobes RJ, Goldbaum FA, Huerta M, Diaz-Orea A, Fleury A, de Aluja AS, Cabrera-Ponce JL, Herrera-Estrella L, Fragoso G, Larralde C. Improvement of the synthetic tri-peptide vaccine (S3Pvac) against porcine Taenia solium cysticercosis in search of a more effective, inexpensive and manageable vaccine. Vaccine 2006; 25:1368-78. [PMID: 17188784 DOI: 10.1016/j.vaccine.2006.10.018] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2006] [Revised: 10/03/2006] [Accepted: 10/04/2006] [Indexed: 11/29/2022]
Abstract
Vaccination of pigs may curtail Taenia solium transmission by reducing the number of cysticerci, the precursors of adult intestinal tapeworms in humans. Several antigen preparations induce protection against porcine cysticercosis in experimental settings but only one subunit vaccine (S3Pvac) has been tested and proved effective in the field against naturally acquired disease. Besides improving of the vaccine's effectiveness, significant reductions in production costs and in the logistics of its administration are necessary for the feasibility of nationwide control programs. This review highlights the development of several versions of S3Pvac aimed to increase effectiveness, reduce costs and increase feasibility by novel delivery systems and alternative routes of administration.
Collapse
Affiliation(s)
- Edda Sciutto
- Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, México, D.F. 04510, Mexico.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
64
|
Willingham AL, Engels D. Control of Taenia solium cysticercosis/taeniosis. ADVANCES IN PARASITOLOGY 2006; 61:509-66. [PMID: 16735172 DOI: 10.1016/s0065-308x(05)61012-3] [Citation(s) in RCA: 65] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Cysticercosis is emerging as a serious public health and agricultural problem in many poorer countries of Latin America, Africa, and Asia. Caused by the pork tapeworm, Taenia solium, this zoonotic disease forms larval cysts in humans and pigs that can lead to epilepsy and death in humans, reduces the market value of pigs and makes pork unsafe to eat. It occurs where pigs range freely, sanitation is poor, and meat inspection is absent or inadequate, and is thus strongly associated with poverty and smallholder farming. Although theoretically easy to control and declared eradicable cysticercosis remains neglected in most endemic countries due to lack of information and awareness about the extent of the problem, suitable diagnostic and management capacity, and appropriate prevention and control strategies. Human neurocysticercosis occurs when the larval cysts develop in the brain. It is considered to be the most common parasitic infection of the human nervous system and the most frequent preventable cause of epilepsy in the developing world. Thus far the infection has not been eliminated from any region by a specific program, and no national control programs are yet in place. We consider the tools available for combating cysticercosis and suggest simple packages of interventions, which can be conducted utilizing existing services and structures in the endemic countries to provide appropriate and sustainable control of the disease.
Collapse
Affiliation(s)
- Arve Lee Willingham
- WHO/FAO Collaborating Center for Parasitic Zoonoses, Royal Veterinary and Agricultural University, Frederiksberg, Denmark
| | | |
Collapse
|
65
|
Sciutto E, Morales J, Martínez JJ, Toledo A, Villalobos MN, Cruz-Revilla C, Meneses G, Hernández M, Díaz A, Rodarte LF, Acero G, Gevorkian G, Manoutcharian K, Paniagua J, Fragoso G, Fleury A, Larralde R, De Aluja AS, Larralde C. Further evaluation of the synthetic peptide vaccine S3Pvac againstTaenia soliumcysticercosis in pigs in an endemic town of Mexico. Parasitology 2006; 134:129-33. [PMID: 16948875 DOI: 10.1017/s0031182006001132] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2006] [Accepted: 07/04/2006] [Indexed: 11/07/2022]
Abstract
Taenia soliumcysticercosis is a parasitic disease frequently affecting human health and the pig industry in many developing countries. A synthetic peptide vaccine (designated S3Pvac) against porcine cysticercosis has been developed previously as an aid to interrupt transmission and has been shown to be effective. The results of the present study support the effectiveness of the vaccine under endemic field conditions. However, given the time-frame of the vaccination trial, no changes in the local levels of transmission were detectable before and after vaccination using sentinel pigs. Thus, this investigation shows the limited usefulness of single vaccination as the sole means of interruptingTaenia soliumtransmission in an endemic region.
Collapse
Affiliation(s)
- E Sciutto
- Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, AP 70228, Ciudad Universitaria, 04510 México, DF México.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
66
|
Cruz-Revilla C, Toledo A, Rosas G, Huerta M, Flores-Perez I, Peña N, Morales J, Cisneros-Quiñones J, Meneses G, Díaz-Orea A, Anciart N, Goldbaum F, Aluja A, Larralde C, Fragoso G, Sciutto E. Effective Protection Against Experimental Taenia solium Tapeworm Infection in Hamsters by Primo-Infection and by Vaccination with Recombinant or Synthetic Heterologous Antigens. J Parasitol 2006; 92:864-7. [PMID: 16995407 DOI: 10.1645/ge-779r1.1] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
The disease caused by Taenia solium is progressively being recognized as a growing global threat for public human health and pig husbandry that requires the development of effective control measures. A central participant in the taeniasis/cysticercosis transmission network is the human carrier of the adult tapeworm because of its great potential in spreading the infection. Herein, evidence is presented that a primary infection of golden hamsters with orally administered T. solium cysticerci improved the host's resistance against a secondary infection. Likewise, previous vaccination increased the hamster's resistance. Similar high levels of protection (> 78%) were induced by systemic or oral vaccination with the S3Pvac anticysticercosis synthetic peptide vaccine or the highly immunogenic recombinant chimera based on the protective peptide KETc1 bound to Brucella spp. lumazine synthase (BLS-KETc1). Increased resistance after primo-infection and vaccination possibly results from changes in the immune conditions prevailing in the host's intestine. The contribution to protection from the KETc1 and BLS epitopes in a chimeric vaccine is under study. Preventive vaccination of definitive hosts of T. solium against the tapeworm, the most relevant step in the taeniasis/cysticercosis transmission, may greatly impact the dynamics of endemic disease and has not been studied or tried previously.
Collapse
Affiliation(s)
- C Cruz-Revilla
- Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, A.P. 70228, México D.F. C.P. 04510, México
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
67
|
Lightowlers MW. Vaccines against cysticercosis and hydatidosis: foundations in taeniid cestode immunology. Parasitol Int 2005; 55 Suppl:S39-43. [PMID: 16337177 DOI: 10.1016/j.parint.2005.11.005] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Recombinant oncosphere antigens have been used in the development of effective vaccines for the prevention of cysticercosis caused by Taenia ovis, Taenia saginata, Taenia solium and hydatid disease caused by Echinococcus granulosus. These vaccines were developed utilizing information gathered from numerous researchers over some 60 years which had established many of the principals concerning immunity to taeniid cestodes in their intermediate hosts. Australian scientists, or scientists with close Australian connections, made seminal early contributions to the understanding of cestode immunology that provided the foundations for more recent application of recombinant DNA methods and the development of practical vaccines. Here, some particular contributions to the field are highlighted from Drs. Michael Gemmell, Michael Rickard, David Heath and Graham Mitchell together with a précis of the recent progress in vaccine development, particularly for prevention of cysticercosis due to T. solium.
Collapse
|
68
|
Miedzybrodzki R, Fortuna W, Weber-Dabrowska B, Gorski A. Bacterial viruses against viruses pathogenic for man? Virus Res 2005; 110:1-8. [PMID: 15845250 DOI: 10.1016/j.virusres.2005.01.009] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2004] [Revised: 01/27/2005] [Accepted: 01/27/2005] [Indexed: 01/24/2023]
Abstract
In this review, we discuss possible models of bacteriophage-virus interactions. The first is based on the mechanism by which phages may interact indirectly with viruses. Its essence is that bacteriophage-derived nucleic acid may inhibit pathogenic virus infection. It seems that this phenomenon can be partly explained on the basis of interferon induction. We also discuss a study by Borecky's group (conducted over two decades ago) which provided some clinical data on the effectiveness of the application of native bacteriophage RNA in the treatment of viral infections. The second interaction model is based on the direct competition of bacteriophages and viruses for cellular receptors for viral cell-entry. The use of bacteriophages as inducers or displayers of antibodies with antiviral action is considered as the third model. In this part of the article, we also discuss other data and hypotheses on conceivable interactions between bacterial and animal viruses. As our current supply of antiviral drugs is quite limited, using natural agents such as bacteriophages as a weapon against pathogenic viruses could be an attractive and cost-efficient alternative, and further studies are urgently needed to test this possibility.
Collapse
Affiliation(s)
- Ryszard Miedzybrodzki
- Bacteriophage Laboratory, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, (Centre of Excellence: IMMUNE), Polish Academy of Sciences, Rudolfa Weigla 12, 53-114 Wroclaw, Poland.
| | | | | | | |
Collapse
|
69
|
Solís CF, Ostoa-Saloma P, Lugo-Martínez VH, Johnston SA, Laclette JP. Genetic vaccination against murine cysticercosis by using a plasmid vector carrying Taenia solium paramyosin. Infect Immun 2005; 73:1895-7. [PMID: 15731096 PMCID: PMC1064979 DOI: 10.1128/iai.73.3.1895-1897.2005] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
A plasmid vector carrying the immunoprotective amino-terminal fragment of Taenia solium paramyosin (VW2-1) was designed for genetic vaccination studies. Mice that were genetically immunized with VW2-1 and challenged by intraperitoneal inoculation of Taenia crassiceps cysticerci showed 43 to 48% reductions in the parasite burden, values which were similar to values obtained previously when the recombinant protein was used.
Collapse
Affiliation(s)
- Carlos F Solís
- Department of Immunology, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, A.P. 70228, Ciudad Universitaria, C.P. 04510, México D.F., Mexico
| | | | | | | | | |
Collapse
|